Calm before the storm... PAS refresherBig news from the DEA today!
https://www.forbes.com/sites/tomangell/2018/08/16/dea-wants-more-marijuana-grown-and-fewer-opioids-produced-in-2019-really/#60df7dc814cb
PAS
Pascal Biosciences, Inc. (PAS, formerly bioMmune Technologies Inc.) is a drug discovery and development company focused on harnessing the body’s immune system to fight cancer.
FEB 21, 2018 PR
Pascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells
- The Company has discovered certain cannabinoids that enhance the immunogenicity of tumor cells, rendering them more susceptible to recognition by the immune system. This discovery is important because the leading class of new cancer fighting agents, termed “checkpoint inhibitors”, activates the immune system to destroy cancer cells.
- There is a growing body of research demonstrating the effectiveness of cannabinoids in the treatment of cancer symptoms, including nausea, appetite enhancement, and pain management.
- Pascal is the first to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy.
-“We are very excited about this novel discovery,” commented Dr. Patrick Gray, CEO of Pascal Biosciences. “Cannabinoids typically have good pharmacological properties, as most have low toxicity and are easily absorbed into the blood, which are great advantages for drug development. In combination with immune checkpoint inhibitors, cannabinoids may significantly improve cancer care. We look forward to soon translating our results into clinical studies.”
JUNE 18, 2018 PR
Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration
- Pascal has been licensed by the US Drug Enforcement Administration (DEA) to conduct research and development on cannabinoids.
- Pascal is one of only a few organizations with a Schedule I Researcher license in the United States that is not a university. Obtaining a DEA Schedule I Researcher license is a rigorous process, requiring a well-documented line of scientific investigation in a formal application, inspection of laboratory facilities, review of Pascal’s plans for record-keeping, and confirmation of facility security. “Receiving our Schedule I DEA license allows us to immediately conduct advanced R&D on cannabinoids, with a goal of conducting clinical trials on cancer patients as soon as possible”, commented Dr. Patrick Gray, CEO at Pascal.
- Dr. Jeffries was the first scientist to discover specific cannabinoids that can increase the immune recognition of both mouse and human cancer cells. Together, both labs have greatly extended this work. Over 375 natural and synthetic cannabinoids have been tested, and the most potent and safe cannabinoids have been identified.
- “Together we have made great progress in developing a cannabinoid for cancer. Pascal’s continued financial support will enable a lead product to complete preclinical efforts for treatment of patients with cancer.”
- In addition to Pascal being awarded the Schedule I Researcher license by the U.S. DEA, Dr. Jefferies’ lab has received approval from Health Canada
July 16, 2018
Pascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors
- Ms. Eastland is a seasoned strategic and financial executive with more than 25 years of experience in public and private biotechnology companies. Most recently she was Chief Business Officer and Chief Financial Officer of Cascadian Therapeutics, where she negotiated and managed the $810M acquisition by Seattle Genetics in March 2018.
- Ms. Eastland has strong relationships with investors, investment bankers and analysts covering the U.S. public biotech sector, and excellent experience in partnering, acquisitions, collaborations, and licensing. She will work closely with Pascal to align our scientific strategy with our financial goals.”
- Ms. Eastland held various financial and strategic management positions at publicly-traded biotechnology companies including Dendreon and Amgen.
Big things coming...
GLA